{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:07:20Z","timestamp":1777352840177,"version":"3.51.4"},"reference-count":39,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2019,7,30]]},"DOI":"10.1536\/ihj.18-337","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T22:03:57Z","timestamp":1562882637000},"page":"886-898","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Nicorandil on All-Cause Mortality and Cardiac Events in CAD Patients Receiving PCI"],"prefix":"10.1536","volume":"60","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, West China Hospital, Sichuan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[{"name":"Medical Affairs, Merck Serono Co. Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Yao","sequence":"additional","affiliation":[{"name":"West China School of Medicine, Sichuan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanjian","family":"Liu","sequence":"additional","affiliation":[{"name":"Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Du","sequence":"additional","affiliation":[{"name":"Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University"},{"name":"West China Medical Publishers, West China Hospital, Sichuan University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, <i>et al<\/i>. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016; 4: 256.","DOI":"10.21037\/atm.2016.06.33"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Li L, Pan Y, Dai L, <i>et al<\/i>. Association of Genetic Polymorphisms on Vascular Endothelial Growth Factor and its Receptor Genes with Susceptibility to Coronary Heart Disease. Med Sci Monit 2016; 22: 31-40.","DOI":"10.12659\/MSM.895163"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yang J, Zhang J, Cui W, <i>et al<\/i>. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. Anatol J Cardiol 2015; 15: 125-31.","DOI":"10.5152\/akd.2014.5207"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nomura T, Keira N, Kojima A, <i>et al<\/i>. Effects of cardiologist experience on outcomes of patients with ST-elevated myocardial infarction treated with primary PCI in a local area in Japan. Int Heart J 2011; 52: 127-30.","DOI":"10.1536\/ihj.52.127"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Brosh D, Assali AR, Mager A, <i>et al<\/i>. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 2007; 99: 442-5.","DOI":"10.1016\/j.amjcard.2006.08.054"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Niccoli G, Kharbanda RK, Crea F, <i>et al<\/i>. No-reflow: again prevention is better than treatment. Eur Heart J 2010; 31: 2449-55.","DOI":"10.1093\/eurheartj\/ehq299"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Resnic FS, Wainstein M, Lee MK, <i>et al<\/i>. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42-6.","DOI":"10.1067\/mhj.2003.36"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Falk E, Thuesen L. Pathology of coronary microembolisation and no reflow. Heart 2003; 89: 983-5.","DOI":"10.1136\/heart.89.9.983"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Morishima I, Sone T, Okumura K, <i>et al<\/i>. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-9.","DOI":"10.1016\/S0735-1097(00)00865-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Miyoshi T, Ejiri K, Kohno K, <i>et al<\/i>. Effect of remote ischemia or nicorandil on myocardial injury following percutaneous coronary intervention in patients with stable coronary artery disease: A randomized controlled trial. Int J Cardiol 2017; 236: 36-42.","DOI":"10.1016\/j.ijcard.2017.02.028"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stojkovic S, Juricic S, Dobric M, <i>et al<\/i>. Improved propensity-score matched long-term clinical outcomes in patients with successful percutaneous coronary interventions of coronary chronic total occlusion. Int Heart J 2018; 59: 719-26.","DOI":"10.1536\/ihj.17-360"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K (ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J 1999; 20: 51-7.","DOI":"10.1053\/euhj.1998.1354"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Katoh M, Takeda N, Arimoto T, <i>et al<\/i>. Bevacizumab-related microvascular angina and its management with nicorandil. Int Heart J 2017; 58: 803-5.","DOI":"10.1536\/ihj.16-537"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fukui Y, Nozawa T, Ihori H, <i>et al<\/i>. Nicorandil attenuates ischemia-reperfusion injury via inhibition of norepinephrine release from cardiac sympathetic nerve terminals. Int Heart J 2017; 58: 787-93.","DOI":"10.1536\/ihj.16-391"},{"key":"15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","volume":"359","year":"2002","unstructured":"15. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-75.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Markham A, Plosker GL, Goa KL. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60: 955-74.","DOI":"10.2165\/00003495-200060040-00007"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pang Z, Zhao W, Yao Z. Cardioprotective Effects of nicorandil on coronary heart disease patients undergoing elective percutaneous coronary intervention. Med Sci Monit 2017; 23: 2924-30.","DOI":"10.12659\/MSM.902324"},{"key":"18","unstructured":"18. J E, Juneja MS, George T, <i>et al<\/i>. Prevention of no flow\/slow reflow phenomenon in primary PCI by Nicorandil. Indian Heart J 2007; 59: 246-9."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kim JH, Jeong MH, Yun KH, <i>et al<\/i>. Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. Circ J 2005; 69: 306-10.","DOI":"10.1253\/circj.69.306"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Wu M, Huang Z, Xie H, <i>et al<\/i>. Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One 2013; 8: e78231.","DOI":"10.1371\/journal.pone.0078231"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ye Z, Su Q, Li L. The clinical effect of nicorandil on perioperative myocardial protection in patients undergoing elective PCI: A Systematic Review and Meta-Analysis. Sci Rep 2017; 7: 45117.","DOI":"10.1038\/srep45117"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Moher D, Shamseer L, Clarke M, <i>et al<\/i>. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1.","DOI":"10.1186\/2046-4053-4-1"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Balshem H, Helfand M, Sch\u00fcnemann HJ, <i>et al<\/i>. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401-6.","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"24","first-page":"211","volume":"2","year":"2006","unstructured":"24. Miyazawa A, Ikari Y, Tanabe K, <i>et al<\/i>. Intracoronary nicorandil prior to reperfusion in acute myocardial infarction. EuroIntervention 2006; 2: 211-7.","journal-title":"EuroIntervention","ISSN":"https:\/\/id.crossref.org\/issn\/1774-024X","issn-type":"print"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nishimura M, Tokoro T, Nishida M, <i>et al<\/i>. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. Am J Kidney Dis 2009; 54: 307-17.","DOI":"10.1053\/j.ajkd.2009.03.025"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kim JH, Jeong MH, Yun KH, <i>et al<\/i>. Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. Circ J 2005; 69: 306-10.","DOI":"10.1253\/circj.69.306"},{"key":"27","unstructured":"27. GAO Nan, FENG Liang, LI Peng, LIU Lu, JIA Zhi-Jing, CAO Bin-tao, WANG Jie. Analysis of nicorandil on coronary artery stent implantation in patients with IL-10, IL-17 and CRP levels and postoperative restenosis. Chin J Forensic Med 2016; 8: 95-8."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Nameki M, Ishibashi I, Miyazaki Y, <i>et al<\/i>. Comparison between nicorandil and magnesium as an adjunct cardioprotective agent to percutaneous coronary intervention in acute anterior myocardial infarction. Circ J 2004; 68: 192-7.","DOI":"10.1253\/circj.68.192"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Al Shammeri O, Garcia LA. Thrombolysis in the age of Primary Percutaneous Coronary Intervention: Mini-Review and Meta-analysis of Early PCI. Int J Health Sci 2013; 7: 91-100.","DOI":"10.12816\/0006026"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Chen YL, Bhasin A, Youssef AA, <i>et al<\/i>. Prognostic factors and outcomes in young Chinese patients with acute myocardial infarction undergoing primary coronary angioplasty. Int Heart J 2009; 50: 1-11.","DOI":"10.1536\/ihj.50.1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Califf RM, Abdelmeguid AE, Kuntz RE, <i>et al<\/i>. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-51.","DOI":"10.1016\/S0735-1097(97)00506-8"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Usui E, Lee T, Murai T, <i>et al<\/i>. Efficacy of multidetector computed tomography to predict periprocedural myocardial injury after percutaneous coronary intervention for chronic total occlusion. Int Heart J 2017; 58: 16-23.","DOI":"10.1536\/ihj.16-114"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ono H, Osanai T, Ishizaka H, <i>et al<\/i>. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J 2004; 148: E15.","DOI":"10.1016\/j.ahj.2004.05.014"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kawai Y, Hisamatsu K, Matsubara H, <i>et al<\/i>. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J 2009; 30: 765-72.","DOI":"10.1093\/eurheartj\/ehp077"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Hwang J, Lee HC, Kim BW, <i>et al<\/i>. The effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina. J Cardiol 2013; 62: 77-81.","DOI":"10.1016\/j.jjcc.2013.03.017"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kim SJ, Kim W, Woo JS, <i>et al<\/i>. Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial. Int J Cardiol 2012; 158: 88-92.","DOI":"10.1016\/j.ijcard.2011.01.011"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Murakami M, Iwasaki K, Kusachi S, <i>et al<\/i>. Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting. Int J Cardiol 2006; 107: 48-53.","DOI":"10.1016\/j.ijcard.2005.02.034"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Isono T, Kamihata H, Sutani Y, <i>et al<\/i>. Nicorandil suppressed myocardial injury after percutaneous coronary intervention. Int J Cardiol 2008; 123: 123-8.","DOI":"10.1016\/j.ijcard.2006.11.219"},{"key":"39","unstructured":"39. Chandler J, Higgins JP, Deeks JJ, Davenport C, Clarke MJ. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Cochrane Community. Available at: http:\/\/community.cochrane.org\/book_pdf\/764. Accessed April 8, 2019."}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/4\/60_18-337\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T03:43:17Z","timestamp":1564198997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/4\/60_18-337\/_article"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.18-337","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]}}}